Show UniProt / TrEMBL protein name		View in Fasta format (DNA)		View as list

# Haemophilus influenzae 86-028NP, 86-028NP

>NTHI1060 predicted cation/multidrug efflux pump
MYEEIRMKFTDIFIRRPVLAVSISLLMIILGLQAISKLAVREYPKMTTTV
ITVSTAYPGADANLIQAFVTSKLEESIAQADNIDYMSSTSAPSSSTITIK
MKLNTDPAGALADVLAKVNAVKSALPNGIEDPSVSSSSGGSGIMYISFRS
KKLDSSQVTDYINRVVKPQFFTIEGVAEVQVFGAAEYALRIWLDPQKMAA
QNLSVPTVMSALSANNVQTAAGNDNGYYVSYRNKVETTTKSVEQLSNLII
SSNGDDLVRLRDIATVELNKENDNSRATANGAESVVLAINPTSTANPLTV
AEKIRPLYESIKTQLPDSMESDILYDRTIAINSSIHEVIKTIGEATLIVL
VVILMFIGSFRAILIPILAIPISLIGVLMLLQSFNFSINLMTLLALILAI
GLVVDDAIVVLENIDRHIKAGETPFRAAIIGTREIAVPVISMTIALIAVY
SPMALMGGITGTLFKEFALTLAGAVFISGVVALTLSPMMSSKLLKSNAKP
TWMEERVEHTLGKVNRVYEYMLDLVMLNRKSMLAFAVVIFSTLPFLFNSL
SSELTPNEDKGAFIAIGNAPSSVNVDYIQNAMQPYMKNVMETPEVSFGMS
IAGAPTSNSSLNIITLKDWKERSRKQSAIMNEINEKAKSIPEVSVSAFNI
PEIDTGEQGAPVSIVLKTAQDYKSLANTAEKFLSAMKASGKFIYTNLDLT
YDTAQMTISVDKEKAGTYGITMQQISNTLGSFLSGATVTRVDVDGRAYKV
ISQVKRDDRLSPESFQNYYLTASNGQSVPLSSVISMKLETQPTSLPRFSQ
LNSAEISAVPMPGISSGDAIAWLQQQANDNLPQGYTYDFKSEARQLVQEG
NALTTTFILAVVIIFLVLAIQFESIRDPMVIMISVPLAVSGALVSLNILS
FFSIAGTTLNIYSQVGLITLVGLITKHGILMCEVAKEEQLNYGKTRIEAI
THAAKVRLRPILMTTAAMVAGLIPLLYATGAGAVSRFSIGIVIVAGLSIG
TIFTLFVLPVVYSYIATEHKPLPVFDENKTTH
>NTHI0153 possible type I restriction enzyme M subunit
MDFEKKFTALFKSIAPQYRRSEVFYDFITIFALEFYLIIYGAQADESLRQ
RYQTAGEHYNEDEKQALSRLFNIIVEALEHKTYDFLGSVFMSLDLGDQYK
AQYFTPSHIAHLMAAVTLSDCHSLIKKRGFLTLQEPTCGSGVMIIEAYNY
LREEDFNPQQQMWAQARDLDFTAALMCYIQMTLLHIPGEVIIGNTLKDEV
NYHLYTPAHIMGNWNKKLESADSYTEAEYQVIEPEPVEEPPLDIDWENEP
MFY
>NTHI1212 conserved hypothetical ABC transporter ATP-binding protein
MFNKIFSWFENRLNPYPESNPTTPKKGLFRFIWSSITGMKGWIFLLAILT
VGTGVMEAVLFQFMGTLVDWLGTFTPERLWQEKSHLLIGMAALLLISIVW
GFLASAVHLQTLQGVFPMRLRWNFHRLMLGQSLSFYQDEFAGRVSAKVMQ
TALAVRDTVLTLADMFVYVLVYFITSGVVLVALDSWFLLPFITWIILFGL
ILRTLIPKLSKTAQRQADARSLMTGRITDAYSNIATVKLFSHGSREATYA
KRSMQDFMVTVHAQMRLATSLDTLTYATNILLTLSTAILGIILWKNGQVG
VGAIATATAMALRVNGLSRWIMWESARLFENIGTVNDGMNTLTKPHTIVD
KPQASPLQVKQGEIKFNDITFAYDPTKPLLNHFNLTIKPGEKVGLIGRSG
AGKSTIVNLLLRFYEAQQGEITIDGQNVLNVQQESLRRQIGLVTQDTSLL
HRSVRDNIIYGRPNATDEEMVLAAERAEAADFIPFLSDSQGRKGYDAHVG
ERGVKLSGGQRQRIAIARVMLKDAPILLLDEATSALDSEVEVAIQESLDK
MMENKTVIAIAHRLSTIAAMDRLIVLDKGQIVEQGTHAELLELNGLYAKL
WNHQSGGFLSGSAE
>NTHI0785 probable ABC transporter, ATP-binding protein
MRKNGFVVMGHLLKLVTPLAHIMAFTITMGTLGFLAAIFIMVFGAMGLVN
LLNFDTHLSFSGILTALIVLAVARGVLRYLEQMSGHYIAFKLLALLRDKV
FSSLRRLAFVKLQDKQAGQLVSLVTNDIELLEVFYAHTIAPIMIAFFTSA
ILLLVFAHLSGWFVVVALAAYLTVGVILPIITTKLAREDGRRYRELVGEM
NDFFLDSVRGMKEIQLFGYAQQRLAEIQQRSQKIDTAFERIKDQEAKVRV
YTEVAVSVFNIIMLFTGLILFSLDKIDFAAFLIGVILLMSSYGPVIALSN
LSSNLLQTLASGERVLSLLAEEPELKDVESAVDLKDVSRIDVENLNFAYG
EEQILSDVSLSVKKGEILGIHGRSGSGKSTLLKLLMRFYDPKSGSIKING
ETLPNINTCSLRDNMAYITQQTYIFNETIEENIRLARRDATLEEIMEAAK
KASIHDFILSLPQGYQTKMTELGGNLSDGEKQRIGIARAFLHNAPIILLD
EPTSNLDSLNEAMILKSLLDAKAEKLIILVSHRQSTMAICDQVIGIENGR
MS
>NTHI0411 ampD, AmpD
MQKLKDIEQGILDCRQIQSPHFDKRPNPQDISLLVIHYISLPPEQFGGGY
VDDFFQGKLDPKIHPYFAEIYQMRVSAHCLIERNGRITQYVNFNDRAWHA
GVSNFQGREKCNDFAIGIELEGSNEQPFTDAQYFSLQELTNVIMKSYPKI
TKDRIVGHCDISPGRKIDPGQYFDWERYLSSVKQTV
>NTHI1063 emrA, multidrug resistance protein A
MTKTAIETPSNKSVSNKTNRKKGLSIFILLLLIIGIACALYWFFFLKDFE
ETEDAYVGGNQVMVSSQVAGNVAKINADNMDKVHAGDILVELDDTNAKLS
FEQAKSNLANAVRQVEQLGFTVQQLQSAVHANEISLAQAQGNLARRVQLE
KMGAIDKESFQHAKEAVELAKANLNASKNQLAANQALLRNVPLREQPQIQ
NAINSLKQAWLNLQRTKIRSPIDGYVARRNVQVGQAVSVGGALMAVVSNE
QMWLEANFKETQLTNMRIGQPVKIHFDLYGKNKEFDGVINGIEMGTGNAF
SLLPSQNATGNWIKVVQRVPVRIKLDPQQFTETPLRIGLSATAKVRISDS
SGAMLREKTEPKTLFSTDTLKYDESAVENLIESIIQQNSH
>NTHI0188 hsdM1, putative type I restriction-modification system, methyltransferase subunit
MEHSVHNKLVSFIWSIADDCLRDVYVRGKYRDVILPMFVLRRLDTLLEPS
KDAVLEEMRFQKEELAFTELDDLPLKKITGHVFYNTSKWTLKSLYQTASN
TPQYMLANFEEYLDGFSTNIHEIINCFKLREQIRHMSHKNVLLSVLEKFV
SPYINLTPKEQQDPEGNKLPALTNLGMGYVFEELIRKFNEENNEEAGEHF
TPREVIELMTHLVFDPLKDQIPAIITIYDPACGSGGMLTESQNFIEQKYP
LSESQGERSIFLFGKETNDETYAICKSDMMIKGDNPENIKVGSTLATDSF
QGNHFDFMLSNPPYGKSWSKDQAYIKDGNEVIDSRFKVTLPDYWGNVETL
DATPRSSDGQLLFLMEMVSKMKSPNDNKIGSRVASVHNGSSLFTGDAGSG
ESNIRRHIIEKDLLEAIVQLPNNLFYNTGITTYIWLLSNNKPEARKGKVQ
LIDASLLFRKLRKNLGDKNCEFVPEHIAEITQNYLDFTAKARETDSQNEA
VGLASQIFDNQDFGYYKVTIERPDRRSAQFTAENISPLRFDKALFEPMQY
LYRQYGEQIYNAGFLAQTEQEITAWCEAQGIALNNKNKTKLLDVKTWEKA
AALFQTASTLLEHFGEQQFDDFNQFKQAVECRLKAEKIPLSATEKKAVFN
AVSWYDENSAKVIAKTLKLKPNELDALCQRYQCQADELADFGYYATGKAG
EYILYETSSDLRDSESIPLKQNIHDYFKAEVQAHISEAWLNMESVKIGYE
ISFNKYFYRHKPLRSLAEVAQDILALEKQADGLISEILEA
>NTHI0314 hsdM2, putative type I restriction-modification system methyltransferase subunit
MAAAIQQRAELQRRIWQIANDVRGSVDGWDFKQYVLGTLFYRFISENFAN
YIEAGDESVNYAQLPDEIITPDIKTDAIKTKGYFIYPSQLFKNVAANAGN
NPNLNTDLKQIFTDIENSATGFPSEQDIKGLFADFDTTSNRLGNTVKDKN
DRLTAVLKGVAELDFGKFEDNHIDLFGDAYEYLISNYAANAGKSGGEFFT
PQSVSKLIAQIAMHGQTSVNKIYDPAAGSGSLLLQAKKQFDEHIIEEGFF
GQEINHTTYNLARMNMFLHNINYDKFDIALGNTLMEPQFGDDKPFDAIVS
NPPYSVKWAGSDNPTLINDERFAPAGVLAPKSKADFAFILHALSYLSGKG
RAAIVSFPGIFYRGGAEQKIRQYLVDNNFVETVIALAPNLFYGTSIAVNI
LVLSKHKPNTQTQFIDASGLFKSATNNNILEEEHIEQILKLFANKEDVPH
LAKSVSFEEIAQNDHNLAVSSYVEQKDTREVINIDELNAQIRETVTNIDR
LRAEIDKIVAEIEG
>NTHI1838 hsdM3, putative type I restriction enzyme HindVIIP M protein
MQARRDTKIVDENHTLQQAFLNDLDEKLWSSADKLRQQLDAANYKHIVLG
LIFLKYISDNFTHQQEKIQAELSDAENPLYLDRTFFDTEEEYQEALTAEL
ENRDYYTADNVFWVPASARWQALQEVSILNTGAELPWGGKFSGVAKLIDD
AFDAIEKDNEKLKGVLQRISGYAVNEDTLRGLIILFSDTNFTRPTYNGEP
VHLGAKDILGHVYEYFLGRFAQAEGKRGGQYFTPKSIVSLIVEMLEPYSG
RVYDPAMGSGGFFVQTERFITAHQGNINNVSIYGQEFNPTTWKLAAMNMA
IRGIDYDFGKHNADSFTQPQHIDKKMDFIMANPPFNISDWWSESLADDPR
WAYGTPPKGNANFAWLQHMIYHLSPNGKMALLLANGSMSSQTNNEGEIRK
AIINADLVECMVALPGQLFTNTQIPACIWFLNRNKKRKGEVLFIDARQIG
YMKDRVLRDFTADDIAKIADTLHTWQKSDGYEDQAAFCKSATLEEIKDND
FVLTPGRYVGTAEQEDDGVPFAEKMQNLTALLKEQFAKSAELEAEIKKNL
GGLGYE
>NTHI0193 hsdR1, putative type I site-specific restriction-modification system, R subunit
MVSGTKEKDLEIAIEKALTGTWRENMENKLGEPKAEYLPRHHGFKLAFSQ
DFDAQFAIDTRLFWQFLQTSQEAELARFQQLNPNDWQRKILERLDRQIKK
NGVLHLLKKGLDIDSAHFDLLYPVPLASSGEKVKQRFEQNLFSCMRQVPY
SASSNETVDMVLFANGLPIIALELKNHWTGQTAIDAQKQYLNRDLSQTLF
HFGRCLAHFALDTEEAYMTTKLAGPATFFLPFNLGNNCGKGNPPNPNGHR
TAYLWQEVFGKASLANIIQHFMRLDGSTKDPLDKRTLFFPRYHQLDVVRR
LIADVSEHGVGKRYLIQHSAGSGKSNSITWLAYQLIEAYPRNEKAANGRE
ADRPIFDSVIVVTDRRLLDKQLRDNIKDFSEVKNIVAPALSSAELRQSLE
QGKKIIITTIQKFPFIVDGIADLGDKQFAVIIDEAHSSQSGSAHDNMNRA
IGKTEDLDAEDVQDLILQTMQSRKMHGNASYFAFTATPKNSTLEKFGEKQ
ADGKFKPFHLYSMKQAIEEGFILDVIANYTTYKSFYEITKSIEDNPEFDS
KKAQSRLKAYVERSQQTIDTKAEIMLDHFIYQVFNRKKLKGKAKGMVVTQ
NIETAIRYFQALKHLLAGRGNPFKIAIAFSGSKVVDGVEYTEAEMNGFAE
SETKEYFDQDEYRLLVVANKYLTGFDQPKLCAMYVDKKLSGVLCVQALSR
LNRSANKLSKRTEDLFVLDFFNSVEDIQQAFEPFYTSTSLSQATDVNVLH
DLKDRLDETGVYEQAEVNDFTEGYFANKDAQQLSSMIDVAVQRFDDELEL
DLDRNEKVDFKIKAKQFLKIYGQMASIINFENIAWEKLYWFLKFLVPKLK
VQDPMDEFDEILDAVDLSSYGLARTKLNYSIKLDDEETELDPQNPNPRGT
HGEDKEKDPIDEIIRVFNERWFQDWSATPDEQRVKFINITERIRSHKDFE
QKYQNNPDIHTRELAFQAILRDVMSERHRDELELYKLFAKDAAFRTAWTQ
SLQRALAG
>NTHI0318 hsdR2, putative type I restriction-modification system
MTQYKTIAESNNFIVLDQYNKFVEEPNAGYQTEGSLEREFIRDLQAQGYE
YLQGLNNHDELIKNLRVQLQRLNNVIFSDAEWQRFLEEYLDKPSDNLIEK
TRKIHDDYIYDFVFDNGRIQNIYLLDKKNLANNSLQVINQFEQTGSYDNR
YDVTILVNGLPLVHIELKKRGVAIREAFNQIHRYSKESFNKENSLFKYIQ
IFVISNGTDTRYFANTTKRNKNSYDFTMNWATAKNTLIKDLKDFTATFLQ
KNTLLNVLVNYCVFDVSDTLLIMRPYQIAATERILWKIKSSYHAKNWSNK
ESGGYIWHTTGSGKTLTSFKASRLATELDFIDKVFFVVDRKDLDYQTMKE
YQRFSPDSVNGSESTAGLKRNIEKDDNKIIVTTIQKLNNLMKSEENLSIY
QKQVVFIFDEAHRSQFGEAQKNLKRKFKKFYQFGFTGTPIFPENALGAET
TTSVFGTELHSYVITDAIRDDKVLKFKVDYNDVRPQFKALETEKDPEKLT
ALEQKQAFLHPERIKEISQYLLNNFKQKTHRLNATGKGFNAMFAVSSVEA
AKRYYETLQNLQAEQEHPLKIATIFSFAANEEQDAIGDIPDETFEPTALN
STAKEFLTKAIDDYNHYFGTNYGVDSQSFQNYYRDLAKRVKNQEVDLLIV
VGMFLTGFDAPTLNTLFVDKNLRYHGLMQAFSRTNRIYDTTKTFGNIVTF
RDLEQNTIDAITLFGDDNTKNMVLEKSYETYFNGDENQRGYLEVVQELQN
RFPNPTEIETEQDKKEFVKLFGEYLRVENILQNYDEFAALQALQAVDLND
PIAMEKFKQVHYVNDEQIAEMLKVPTLPVRAEQDYRSTYNDIRDWLRQRK
EGNDKDNSPINWDDVVFEVDLLKSQEINLDYILALIFEHHKKNQDKEVLI
DEIRRTVRSSLGNRAKESLIVDFINQTNLDDIPDKATLIDSFFLFAQAEQ
RKEAESLIQEENLNVDAAKRYISTSLKREYASENGTALNEVLPKMSPLTP
QYLTKKQTIFQKIAAFVEKFKGVGGKI
>NTHI1843 hsdR3, putative type I restriction enzyme HindVIIP R protein
MLNENDIEQLTLQRLQSLGWEYRYGKDLPVHEGEFSRGNLSGVVFIEQLR
EAVRKLNPQLPESAVDSVVKSATKSDIGDLVVRNQTFYKLLRDGVRVEYQ
DDGEQKIEMARLVDFEHGENNRFVAVNQLEIRSRKGGKRIPDIIGFVNGL
PLVVFELKNPLRESADLLQAFNQFETYKDEIAELFVYNQALIISDGIAAR
LGSLSADFQRFTPWKVVDEKNKSVRLYFDDELQSLLNGLMQPEDLLDYIR
YFVLFERDSVGKTIKKIAAYHQYYGVNEAVESTIFATSEQGDKRIGVMWH
TQGSGKSISMLFYAGKLLAQPELKNPTIVVVTDRNDLDGQLFQTFSSGKD
LIKQTPQQVEDRDQLRQLLAQNEVGGVFFTTIQKFALNEEESRFPILNER
NNIIVISDEAHRSQYGFTQKLHNGKFQTGYARHLRDALPNASFIGFTGTP
ISLEDKDTQDVFGRYVSIYDLQDAVEDGATVPIVYEARQIKLAENANHDE
LFAEIDELLEGEENPKLRLREKLLGSEARLHDLAIDFVQHFAKRNEVVDS
KAMMVVSSRQICVDLYNQIIALHPEWHSDNINEGAIKIVMTGSASDASEM
QKHVYSKQEKQTLERRFKDPNDPLKVVIVRDMWLTGFDAPCCNTMYLDKP
MKGHNLMQAIARVNRVFRNKSRENGGLIVDYVGIADELEKATRQYTNSQG
KGKLADSVIDVFFKMKEHLEVIRSLFATPVEGKTFDVQAALEKDNPNDLL
MAIRFAANHILSLDQLSFDGKAHEQHWFNKKETEPRKKAFLKTAGLVKKG
YMLCGTLAEVEPYNQEIAFYDAVRAILTKREQKGTGTNERQILLKKLVNQ
TVYSEGVIDLFDLLEKPQPQISLLSEEFLQTVKNSPTKNLWVSAMERYLA
SEIKVKSGTNLTLQKDFERRLKEALNQYHNHNLTVVEILDELFKMSQDFQ
ERLALGKKLGLTKEELAFYEALSQNQSAKDLMGDEVLSKLAKEITETLRK
SVTIDWQYKEAVRARIRLLVRRALQKYKYPPDKQEEAVTYVIKQAEEIAE
DLTGL
>NTHI0192 hsdS1, putative type I site-specific restriction-modification system, S subunit
MRRYERYKDSGVDWLGEVPSHWELKRLKQLFVEKKHKQSLSLNCGAISFG
KVIEKSDDKVTEATKRSYQEVLKGEFLINPLNLNYDLISLRIALSEIDVV
VSAGYIVLKEKQIINKKYFSYLLHRYDVAYMKLLGSGVRQTINYGHISDS
ILVIPPLSEQQKIAQFLDDKTAKIDQAVDLAEKQIALLKEHKQILIQNAV
TRGLNPDVPLKDSGVEWIGQVPEHWDVQRSKFIFKKIERKVNEEDQIVTC
FRDGQVTLRANRRTEGFTNALKEHGYQGIRKGDLVIHAMDAFAGAIGISD
SDGKATPVYSVCLPHDKQKIDVYFYAYYLRNLALSGFISSLAKGIRERST
DFRYSDFAELLLPIPPYLEQQKIADYLDKQTSKIDRAIALKTAHIEKLKE
YKSVLINDVVTGKVRV
>NTHI0315 hsdS2, putative type I restriction-modification system specificity protein
MKNNRTFLEKLLDGSEVEWKPLDEVANIVNNARKPVKSSSRVSGNIPYYG
ANNIQDYVEGYTHEGEFVLIAEDGSASLENYSIQWAVGKFWANNHVHVVN
GKEKLNNRFLYHYLTNMNFIPFLAGKERAKLTKAKLQQIPIPIPPLSVQT
EIVKILDALTALTSELTSELILRQKQYEYYREKLLSEEELGKVGFEWKTI
DEISKKISSGGTPTTSNNGYYDNGTIPWLRTQEVDFKEIWDTNIKITEDA
LNNSSAKWIPANCVIVAMYGATVGKTAINKIPLTTNQACANIEINDKLAC
YRYIFHYLTSKYEYIKSLGSGSQTNINAQIIKKLKVPVPPIEEQYRIVSI
LDKFETLTNSITEGLPLAIEQSQKRYEYYRELLLNFPSRE
>NTHI1839 hsdS3, putative type I restriction enzyme HindVIIP specificity protein
MSKIPLNEFITLQRGFDLPSNKRISGSVPVVASTGIAGYHNEIKVKAPGV
VIGRSGSIGGGQYIEKDFFPLNTTLYVKDFKGHYPRFIYYLLKSIDFTSF
NVGTGVPTLNRNHLSSILISDLGIEKEKEIANILGSLDQKIQLNTQINQT
LEQIAQALFKSWFVDFDPVRAKVQALSDGLSLEQAELAAIQAISGKTPEE
LTALSQTQPERYAELAETAKAFPCEMVEVDGVEVPKGWEVKALDEIANYQ
NGLALQKFRPEDDEPFLPVVKIAQLRQGYADGDEKAKANIKPECIIDNGD
VIFSWSGSLLVDIWCGGKAALNQHLFKVSSKEYPKWFYYFYTKHHLTEFQ
RIAYDKAVTMGHIKREHLSAAKCIVPNDELLANKTLENILEKIIFNRLEN
FNLQNTRDLLLPRLLNGELNG
>NTHI1585 lolD, lipoprotein releasing system ATP-binding protein LolD
MNNYLLKCENINKFYQEGENQTQVLKGVSFSMEPAELVAIVGSSGSGKST
LLHTLGGLDQPSSGEVFINGQSLQKASANELAALRNRYLGFVYQFHHLMA
DFTALENVMMPMLIGHQNKTEAKDRAEKMLSAVGLSHRITHRPSALSGGE
RQRVAIARALVNNPSLVLADEPTGNLDHKTTESIFELIQQLNQEQNIAFL
LVTHDMGLAEKLSRRLVMQDGLLKEGA
>NTHI0072 msbA, lipid A export ATP-binding protein MsbA
MQEQKLQENDFSTLQTFKRLWPMIKPFKAGLIASGIALVFNALADSGLIY
LLKPLLDDGFGKANHSFLKIMAFVVVGMIILRGVTNFISNYCLAWVSGKV
VMTMRRRLFKHLMFMPVSFFDRNSTGKLLSRITYDSEMIASSSSGSLITI
VREGAYIISLLAVMFYTSWELTLVLFVIGPIIAVLITIVSKIFRKLSKNL
QDSMGELTATTEQMLKGHKVVISFGGQFVEEERFNKVSNNMRRKGMKMVT
ADSISDPVVQIIASLALVAVLFLATTPLIAEDNLSAGSFTVVFSSMLAMM
RPLKSLTNVNSQFQRGMAACQTLFAILDLEPEKDNGTYKAEPAKGALEFK
NVSFAYQGKEELALNNISFSVPAGKTVALVGRSGSGKSTIANLVTRFYDI
EQGEILLDGVNIQDYRLSNLRENCAVVSQQVHLFNDTIANNIAYAAQDKY
SREEIIAAAKAAYALEFIEKLPQGFDTVIGENGASLSGGQRQRLAIARAL
LRNSPVLILDEATSALDTESERAIQSALDELKKDRTVIVIAHRLSTIENA
DEILVIDHGEIRERGNHKALLEQNGAYKQLYSMQFSG
>NTHI1430 norM, probable multidrug resistance protein NorM
MNFRLLSQYHADIKKLIKISLPILLAQIAQNSMGLADTIMAGRVSSTDMA
AISIGASIWMPLMLFGQGLLLALPPTISYLNGSGQRHRIAHQVRQGIWLV
LGVSIPLGLLIYFCEIPLQYMQMESKMSDLARDYLHAMLWGLPAYLMLIN
FRCLNDGIAKTKPAMVITFLGLLINIPLNYIFIYGKFGIPAFGAVGCGIA
TAIVNWAMCLMMIFYSYTNAQERSLKVFSQLIEMPNLKTLKKLLRLGLPI
AIAICCEVALFALTSLMLSPLGATIVASHQITLNTSSFIFMFPMSIGMAA
TILVGQALGTGSPQNAKKIGYAALLLGLTVTIITALITIFFRYEIASIFV
TDEIVIAMAANLLLFAALYQFSDTIQMVVGGILRGYKDTKMILYITLFSY
WVIGVPLGYTLGRTDWLIPHIDAKGFWIAFVVSLTFAAFLLSLRMKKMQA
MSDNAILQRLEKLK
>NTHI1400 sapB, ABC-type transport system, permease protein, involved in antimicrobial peptide resistance
MFWSVLRHILWVALLLLVLSLLGFVILLRDPLNANLVTQNIYIGYFHYLG
TLLQGDFGITYNGGKSLMNLILTVLPPTLELCFITLFLAFIFGLPLGIIS
AVNSEQVFAKSLQILSYVGLSIPIFWLAPILLYVAALSHWEIAAIGQYNL
LYEIKPITGFPVIDMWFMEVPYRTKIVQNILQHLALPTLVLCILPTMEII
RIIHQRAEYILNQNFSKVATTRGWSKWKILHQYVFRNTFPLLVPQVPRVF
TLVLTQCMLVETALGWPGIGRWLINAVNEQDYNSIAAGVIVIGVCIILID
TFTKIFTFILDPFKKKGWYAR
>NTHI1399 sapC, ABC-type transport system, permease protein, involved in antimicrobial peptide resistance
MQDKEPDEFRESTSIFQIWLRFRQNTIALFSFYLLIALIFTALFASYLAP
YADNRQFIGQELMPPSWVDRGKIAFFFGTDDLGRDILSRLIMGTRYTLGS
ALLVVFSVAIIGGALGIIAGLLKGIKARFVGHIFDAFLSLPILLIAVVIS
TLMEPSLWNAMFATLLAILPYFIHTIYRAIQKELEKDYVVMLKLEGISNQ
TLLKSTILPNITVIYIQEVAHAFVIAVLDISALSFISLGAQRPTPEWGAM
IKDSLELLYLAPWTVLLPGFAIIFTILLSIIFSNGLTKAINQHQE
>NTHI1398 sapD, ABC-type transport system, ATP binding component, involved in antimicrobial peptide resistance
MALLDICNLNIEIQTSNGRIKIVDGVNLSLNEGEISGLVGESGSGKSLIA
KVICNAIKENWIITADRFRFHDIELLKLSPNKRRKIVGKEISMIFQNPLS
CLDPSRKIGKQLIQNIPNWTFKNKWWKWFGWKKRRAIELLHRVGIKDHRD
IMASYPNELTEGEGQKVMIAMAVANQPRLLIADEPTNTLESTTALQVFRL
LSSMNQNQGTTILLTSNDIKSISEWCDQISVLYCGQNTESAPTEILIESP
HHPYTQALINAVPDFTQPLGFKTKLGTLEGTAPILEQMPIGCRLGPRCPF
AQKKCMEKPRRLKIKQHEFSCHYPINLREKNFKEKTTATPFILNCKGNE
>NTHI1397 sapF, ABC-type transport system, ATPase component, involved in antimicrobial peptide resistance
MPLLQVEDLTKTFKGHASLFGRNQFNAVDKVSFTLERKQTLAIIGNNGSG
KSTLVKMIAGIIPPTSGRILFNDRELQYQDAQSRAKHIRMVFQDANSAFN
PRLNIGQILDEPLSLATDWTETQRNEKIFETLSLVGLYPDYTNLNIKHLS
ISQKQRVALARALILAPEIIIIDDAIGNLDASVRIQLLNLTLDLQQRLGI
SYIYVGQDLGVIKHIADTIIVMDDGKMIEYGSPQNLFTDPQTDVTRRLVE
SYFGKILDETAWVKDKNTH